Oncotelic Therapeutics, Inc.
OTLC
$0.047
$0.0024.44%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 208.26% | -59.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 220.95% | -61.01% | |||
| Operating Income | -220.95% | 61.01% | |||
| Income Before Tax | 44.34% | 80.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.34% | 80.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 22.43% | -20.39% | |||
| Net Income | 50.29% | 81.82% | |||
| EBIT | -220.95% | 61.01% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 53.33% | 81.48% | |||
| Normalized Basic EPS | 55.56% | -800.00% | |||
| EPS Diluted | 53.33% | 85.00% | |||
| Normalized Diluted EPS | 55.56% | -800.00% | |||
| Average Basic Shares Outstanding | 0.03% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||